Sign In
Buy ZYME
$22.86
-0.260 (-1.12%)
At Close: Jul 24, 2026
Zymeworks Announces Presentations Highlighting Breadth of Oncology Portfolio at Upcoming Medical Conferences
05:00pm, Thursday, 22'nd May 2025
VANCOUVER, British Columbia, May 22, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeut
Zymeworks Announces Participation in Upcoming Investor Conferences
06:00am, Wednesday, 21'st May 2025
VANCOUVER, British Columbia, May 21, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeut
Zymeworks Presents Preclinical Data on ZW1528 at the American Thoracic Society International Conference
04:15pm, Monday, 19'th May 2025
VANCOUVER, British Columbia, May 19, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeut
Wall Street Analysts Think Zymeworks (ZYME) Could Surge 83.89%: Read This Before Placing a Bet
11:01am, Wednesday, 14'th May 2025
The consensus price target hints at an 83.9% upside potential for Zymeworks (ZYME). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estima
Zymeworks Inc. (ZYME) Q1 2025 Earnings Call Transcript
11:00pm, Thursday, 08'th May 2025
Zymeworks Inc. (NASDAQ:ZYME ) Q1 2025 Earnings Conference Call May 8, 2025 4:30 PM ET Company Participants Shrinal Inamdar - Senior Director, Investor Relations Ken Galbraith - Chair & CEO Paul Moore
Zymeworks Inc. (ZYME) Reports Q1 Loss, Tops Revenue Estimates
06:56pm, Thursday, 08'th May 2025
Zymeworks Inc. (ZYME) came out with a quarterly loss of $0.30 per share versus the Zacks Consensus Estimate of a loss of $0.45. This compares to loss of $0.42 per share a year ago.
Zymeworks Provides Corporate Update and Reports First Quarter 2025 Financial Results
04:05pm, Thursday, 08'th May 2025
VANCOUVER, British Columbia, May 08, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeut
Zymeworks: A Strong Buy With Newly-Approved Cancer Drug, Excellent Financials, And Expansive Pipeline
05:33pm, Monday, 28'th Apr 2025
Zymeworks is rated Strong Buy due to its improved outlook, FDA approval of Ziihera, advancing pipeline, and strong cash position. Zanidatamab (Ziihera) is a key asset with accelerated approval for HER
Zymeworks: Poised For Growth With Platform Validation
10:48am, Monday, 28'th Apr 2025
Zymeworks' FDA approval of Ziihera for HER2-positive biliary tract cancer validates its science, partnerships, and positions it for long-term value creation. Financial stability is evident with $76.3
Zymeworks Presents New Data from Multiple Development Programs at 2025 AACR Annual Meeting
01:00pm, Friday, 25'th Apr 2025
Six posters highlight continued progress across antibody-drug conjugate and T cell engager platforms Novel T cell engager ZW209 demonstrates durable activity in small cell lung cancer; IND submission
Zymeworks Appoints Dr. Sabeen Mekan as Senior Vice President, Clinical Development
06:00am, Monday, 21'st Apr 2025
VANCOUVER, British Columbia, April 21, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherape
Zymeworks to Report First Quarter 2025 Financial Results and Host Conference Call on May 8, 2025
06:00am, Thursday, 17'th Apr 2025
VANCOUVER, British Columbia, April 17, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherape
Insiders Make Huge Purchases of These 4 Biotech Stocks
08:40am, Wednesday, 26'th Mar 2025
After a rough patch, it seems the biotech industry may be staging a comeback. Several biotech firms have gone public this year, and those focused on obesity treatments, gene therapies, and more have h
Zymeworks Announces Participation in Upcoming Investor Conferences
06:00am, Wednesday, 26'th Mar 2025
VANCOUVER, British Columbia, March 26, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherape
Zymeworks to Present Preclinical Data on T cell Engager and Antibody-Drug Conjugate Platforms in Six Posters at AACR Annual Meeting
04:30pm, Tuesday, 25'th Mar 2025
Novel trispecific T cell engager, ZW209, demonstrates potent preclinical efficacy against DLL3-expressing tumors and an encouraging safety profile
